These findings suggest that the synergistic combinations of miR-329 or mirR-449b and TMZ offer a potential therapeutic strategy to modulate NF-κB activity in glioblastoma and, therefore, therapeutic resistance. This evidence concerns the gene NFKB1 and glioblastoma.